Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B D Johnson

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 6, 1997
Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinaseK A Burton, B D Johnson, Z E Hausken, et al.
Journal of Medicinal Chemistry|December 25, 1992
Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAFA Wissner, M L Carroll, B D Johnson, et al.
Journal of Medicinal Chemistry|September 17, 1993
Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitorsR Paul, W A Hallett, J W Hanifin, et al.
Journal of Medicinal Chemistry|November 1, 1985
Imidazo[1,5-d][1,2,4]triazines as potential antiasthma agentsR Paul, J A Brockman, W A Hallett, et al.
JRSM Open|April 21, 2015
Five-year stroke rate in women with signs and symptoms of ischemia undergoing coronary angiography: a retrospective study from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE)A Haftbaradaran, M Zaya, P K Mehta, et al.
International Journal of Obesity (2005)|May 27, 2005
Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE studyS G Terra, S P McGorray, R Wu, et al.
Substance Use & Misuse|August 26, 1998
Dan Waldorf: the scientist and the manL D Harrison, M Backenheimer, M Agar, et al.
Journal of Medicinal Chemistry|August 10, 2001
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activityH R Tsou, N Mamuya, B D Johnson, et al.
Heart (British Cardiac Society)|August 12, 2009
Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) studyD S Krantz, K S Whittaker, J L Francis, et al.
Biochemical Pharmacology|March 23, 1999
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)C M Discafani, M L Carroll, M B Floyd, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Proceedings of the National Academy of Sciences of the United States of America|October 6, 1997
Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinaseK A Burton, B D Johnson, Z E Hausken, et al.
Journal of Medicinal Chemistry|December 25, 1992
Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAFA Wissner, M L Carroll, B D Johnson, et al.
Journal of Medicinal Chemistry|September 17, 1993
Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitorsR Paul, W A Hallett, J W Hanifin, et al.
Journal of Medicinal Chemistry|November 1, 1985
Imidazo[1,5-d][1,2,4]triazines as potential antiasthma agentsR Paul, J A Brockman, W A Hallett, et al.
JRSM Open|April 21, 2015
Five-year stroke rate in women with signs and symptoms of ischemia undergoing coronary angiography: a retrospective study from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE)A Haftbaradaran, M Zaya, P K Mehta, et al.
International Journal of Obesity (2005)|May 27, 2005
Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE studyS G Terra, S P McGorray, R Wu, et al.
Substance Use & Misuse|August 26, 1998
Dan Waldorf: the scientist and the manL D Harrison, M Backenheimer, M Agar, et al.
Journal of Medicinal Chemistry|August 10, 2001
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activityH R Tsou, N Mamuya, B D Johnson, et al.
Heart (British Cardiac Society)|August 12, 2009
Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) studyD S Krantz, K S Whittaker, J L Francis, et al.
Biochemical Pharmacology|March 23, 1999
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)C M Discafani, M L Carroll, M B Floyd, et al.
Pageof 18